Development of antibody surrogates for the treatment of cancers and autoimmune disease

Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, FL 33458, USA.
Current opinion in chemical biology (Impact Factor: 6.81). 12/2010; 14(6):721-7. DOI: 10.1016/j.cbpa.2010.07.002
Source: PubMed


Some therapeutic monoclonal antibodies function by focusing the killing power of the immune system on particular cellular targets, a process known as antibody-dependent cell-mediated cytotoxicity (ADCC). There is considerable interest in developing small-molecule therapeutics that utilize this mechanism of action and so act as a kind of antibody surrogate. Progress and challenges in this interesting field are reviewed here.

Full-text preview

Available from: